Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. - Wikidata - awgldk - TriplyDB

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.

http://www.wikidata.org/entity/Q30251438

about

Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.Moving forward with human papillomavirus immunotherapies.Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook.The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1.Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future.ATVB Distinguished Scientist Award: How Costimulatory and Coinhibitory Pathways Shape Atherosclerosis.Local delivery of checkpoints antibodies.Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors.Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer.Renal complications of immune checkpoint blockade.Delivering safer immunotherapies for cancer.Hypoxia: Signaling the Metastatic Cascade.Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.Elevated T cell activation score is associated with improved survival of breast cancer.Immunoproteasome deficiency in non-small cell lung cancer and its relevance to immunotherapy.A CTLA-4 Antagonizing DNA Aptamer with Antitumor Effect.Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response.Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity.Effective antitumor peptide vaccines can induce severe autoimmune pathology.The antibody repertoire of colorectal cancer.CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.The MeLiM Minipig: An Original Spontaneous Model to Explore Cutaneous Melanoma Genetic Basis.Adverse Events in Cancer Immunotherapy.Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer.Targeting Immune Cell Checkpoints during Sepsis.Versatile and on-demand biologics co-production in yeast.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events.Trial watch: Immune checkpoint blockers for cancer therapy.Synthetic RNA-Based Immunomodulatory Gene Circuits for Cancer Immunotherapy.Immune checkpoint inhibitor-related myocarditis.Immunoengineering with biomaterials for enhanced cancer immunotherapy.Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking.The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and safety.Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives.A Case of Nivolumab-Induced Severe Mononeuropathy Multiplex and Rhabdomyolysis.

P2860

Q28468290-F04BE4A2-5D93-4977-ABCD-827228648757 Q34548319-9BD142B8-5452-4047-957B-33956AC2FE50 Q37473299-8429072B-C9E4-433A-88C4-D395C83F01DE Q38677432-EC4385FC-B689-4A12-9A38-FCC77C760701 Q38684886-D9B00704-13D1-4E7D-8EF6-802726C78E4E Q38687631-DAB4BD57-6C94-4701-87A9-8A123C83EDF9 Q38737500-A1A7971D-D5A5-4AF0-8BFC-F0BD970CE34A Q38817657-ADB2B549-4D8B-47FA-9ACF-5970E4E1E364 Q38948950-CDA8F893-AA35-4DC2-950A-87DFD9A5E2E4 Q39017623-9A41C59F-BF40-4823-A54F-52C98ED9DAAF Q39085984-8F7BE448-A5CB-4E83-A57C-A5757E6D6B0B Q39131602-EE7BCAB4-883C-4A4F-B694-F365FA60B494 Q39330984-36F4D89B-249C-4044-8E15-266228E91F7E Q39456897-D2657CE6-3DAA-4875-A175-28F954D8E4EF Q40204803-6F10DB55-8BBB-4C42-B8BA-A797B3408F74 Q40208127-2642E16B-7E83-4539-A011-0BA509C90D47 Q41428789-AB209519-F56A-4330-9765-A254C3E7C446 Q41538262-C9C967D9-6C79-436D-B291-2DDD7E939E7B Q41701099-0058B0B5-9079-46FD-81B8-6DABC77397B5 Q42204050-FB9B404C-9FDC-4E00-B258-9690FE477107 Q42378431-7E82EF85-D173-45DB-8D80-40FA534E40BA Q42695851-9A9D158D-0090-4F62-9A72-814F906BDBCF Q45217684-74E240EA-E64F-48FA-88D0-C6527169099C Q45952214-7E4F4EA0-C1CC-4435-93B6-FD50DDEEC6F4 Q45955388-0EE29A42-E510-44DD-8C48-6C194837F011 Q46884498-69281FFA-DB66-4E99-BB89-8CDE884B16B3 Q47102520-95C63E65-B6D7-48AC-8388-416D5364FBE4 Q47119885-F980A204-23E4-4C15-986D-613FDF59984D Q47150101-3809601B-85B2-4D01-A1FA-E70CC156E445 Q47192978-1DB4C439-284D-4FD0-AFCA-A0A36B0B6853 Q47221234-394754FD-28FB-4A6C-ABF2-DE20C62F5729 Q47367962-B675E806-3424-4469-90C5-A318A27022CC Q47393365-69AAFCC0-8216-4000-B6B8-54D19329B15D Q47423662-CED02EC6-BF15-4F1C-B1F8-B103BF430A1C Q47633085-7B70C06C-9C1B-45D1-9B35-C6DE7AD593EB Q47732542-41F1D04D-A221-4D21-9082-58D337CC5F04 Q47828100-D56B4A1F-CCBD-4865-BC4A-7441782B9566 Q47916852-A6FD0CB5-5CA7-4CB6-BF5F-4F5E3DB041DA Q47986213-2EB8FF9E-0C21-4FBF-91A2-854641D771DD Q48292401-2F7EE8A3-64C8-45F1-B37D-36F163E5281A

P2860

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.

http://www.wikidata.org/entity/Q30251438

description

2016 nî lūn-bûn

@nan

2016 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.

@ast

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.

@en

type

label

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.

@ast

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.

@en

prefLabel

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.

@ast

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.

@en

P1433

Q30251438-C0072628-5D27-4361-B726-B95B11E5C4F8

P1476

Q30251438-3FED6180-6115-41F8-B77D-D24963EC27CE

P2093

Q30251438-3873F60D-536F-4D68-ACFA-F923AFFCE801

Q30251438-3CED7C4F-5B05-402D-80DD-0409671B78A6

Q30251438-73B0CEE1-CBAD-4A71-B4E8-6334B5B2294F

Q30251438-7534298C-288B-4A46-A900-6C5CA157E2B6

Q30251438-9A51DD82-67CE-4FFB-A1B0-7B029121D155

Q30251438-AA3C879F-F3C5-4CB9-81D1-9495C85A1070

Q30251438-AF6F57DE-C903-44A2-A146-AC31FA71CF62

Q30251438-C84DAF40-A173-4409-A40A-A9F636A0854F

Q30251438-D269BB83-3CAF-45F0-9940-FD22720A7524

Q30251438-E0D34C44-C455-4EF7-9186-1FA6B531BCE2

P304

Q30251438-0E0DDA88-9579-4542-A758-56824F5FCDE1

P31

Q30251438-7FF9A1EF-D82C-4119-8B80-CFFE104F7ED3

Q30251438-bb6ddf11-3bff-4404-bf93-86d71b126b5b

P356

Q30251438-C13D3B1D-300E-4404-9432-DF746782EC54

P407

Q30251438-D73464DD-2AD7-4C0F-A4B6-402B436E550F

P433

Q30251438-DE9D3E63-0946-4ACE-94DD-F1957617F21D

P478

Q30251438-7EAF7508-41AC-4285-AA58-FC110240F2C0

P50

Q30251438-2C9279A4-4A19-46B0-BBA3-D9FAA4B316FF

Q30251438-B3AE0F52-79F6-4461-BF0B-A7B14B2165C5

Q30251438-BCC7A803-1008-462D-9690-98471EA51FD2

Q30251438-E59C0DFF-67A7-495C-A073-881D93F009FF

Q30251438-F2BBFA3C-CEE8-4BE4-BC3C-AE9399B78465

P577

Q30251438-E7450678-26EC-4D1B-9323-425E336AEC9C

P698

Q30251438-BE59B4DA-2390-433E-B9DE-530594D98603

P921

Q30251438-1F12F73A-B09E-4CCC-861C-947C10184F74

P356

NRCLINONC.2016.58

P1433

Nature Reviews Clinical Oncology

P1476

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.

@en

P2093

Ahmad Tarhini

http://www.w3.org/2001/XMLSchema#string

Alexander M M Eggermont

http://www.w3.org/2001/XMLSchema#string

Armandine Berdelou

http://www.w3.org/2001/XMLSchema#string

Aurelien Marabelle

http://www.w3.org/2001/XMLSchema#string

Celine Boutros

http://www.w3.org/2001/XMLSchema#string

Christine Mateus

http://www.w3.org/2001/XMLSchema#string

Cristina Libenciuc

http://www.w3.org/2001/XMLSchema#string

Emilie Lanoy

http://www.w3.org/2001/XMLSchema#string

Emilie Routier

http://www.w3.org/2001/XMLSchema#string

Franck Carbonnel

http://www.w3.org/2001/XMLSchema#string

P304

473-486

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRCLINONC.2016.58

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Alexander Eggermont

Jean-Charles Soria

Caroline Robert

Olivier Lambotte

P577

2016-05-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27141885

http://www.w3.org/2001/XMLSchema#string

P921